Collectively, these findings suggest that RBM10 expression affects the therapeutic sensitivity to EGFR-targeted therapy by modulating the apoptotic response, without a substantial impact on tumor cell proliferation or tumor initiation or growth in the absence of either oncogenic EGFR or EGFR inhibitor treatment in these various systems. Here, EGFR is linked to neoplasm.